ZIVO BIOSCIENCE INC - ZIVO STOCK NEWS

Zivo Bioscience has reported progress in licensing its coccidiosis treatment for broiler chickens. Following positive results from a 42-day study announced in August 2024, Zivo is discussing an exclusive license with major global animal health companies. Due diligence processes are underway, including technical evaluations, patent reviews, and business case assessments. Formal negotiations are expected to start in January 2025, with an agreement anticipated in Q1 2025. Zivo aims for a deal with upfront payment, milestone payments, and royalties. CEO John B. Payne highlighted the product's potential to enhance ionophores and vaccines. Additionally, Zivo is advancing its product targeting Low Pathogenicity Avian Influenza (LPAI) virus in poultry, planning further studies at the University of Delaware to optimize dosage and formulation. Payne noted the active ingredients' effectiveness against both parasitic and viral diseases, offering commercial opportunities.

ZIVO Bioscience (OTCQB: ZIVO) reports positive results from a University of Delaware study evaluating its proprietary active ingredients against Low Pathogenicity Avian Influenza (LPAI) in poultry. The two-part study showed statistically significant findings including reduced viral shedding in infected birds and delayed LPAI transmission when healthy birds were exposed to infected ones.

The study demonstrated that birds receiving ZIVO's ingredients experienced an early significant decrease in viral titers compared to untreated controls. Different product configurations showed varying effectiveness, with some better at lowering viral titer and others at slowing spread, suggesting potential for comprehensive protection through optimal product configuration.

ZIVO Bioscience, Inc. (OTCQB: ZIVO) reports favorable results from a 42-day study of its coccidiosis treatment in broiler chickens. The study, conducted with a major global animal health company, showed that ZIVO's non-antibiotic, immune-modulating product significantly improved growth performance and reduced clinical signs of disease when used in combination with existing treatments. Chickens treated with ZIVO's product alongside an ionophore or vaccination achieved feed conversion ratios comparable to healthy, uninfected birds. This demonstrates the product's potential to enhance current treatment options and its standalone treatment capabilities for coccidiosis, a major challenge in poultry production.

ZIVO Bioscience (NASDAQ: ZIVO) announced the start of a 42-day confirmatory study in partnership with a major global animal health company to validate its non-antibiotic coccidiosis treatment for broiler chickens. This study, building on previous positive results, aims to ensure the product's effectiveness under commercial poultry production conditions. The study compares ZIVO's product with traditional ionophore-based treatments and explores combinations with coccidiosis vaccines. The goal is to provide a sustainable, antibiotic-free solution to address the $10 billion annual loss in the poultry industry due to coccidiosis. The results are expected by September.

Zivo Bioscience, Inc. announces positive findings from a 42-day coccidiosis challenge study, demonstrating the impact of its product on broiler production. The product reduces intestinal damage caused by the Eimeria parasite, leading to improved feed utilization and a better Feed Conversion Ratio (FCR), which drives profitability. These results position ZIVO's product as a potential game-changer in the poultry industry, offering improved outcomes at cost parity or better.

Zivo Bioscience, Inc. (ZIVO) has successfully uplisted its common stock from the OTC Pink Market to the OTCQB Venture Market, under the ticker symbol 'ZIVO'. This move is aimed at enhancing visibility, improving market access, and increasing liquidity for shareholders. The OTCQB listing requires compliance with higher standards, financial reporting with the SEC, minimum bid price test, audited financials, and company verification.

Zivo Bioscience, Inc. announces positive results from a 42-day coccidiosis challenge study, demonstrating the effectiveness of its immune-modulating treatment for broiler chickens. The study showed that the product candidate is comparable to a market-leading anticoccidial product containing antibiotics and chemicals. Zivo will pursue a partnership with a global animal health company for commercializing its coccidiosis product.

Zivo Bioscience, Inc. is conducting a 42-day study to validate the efficacy of its immune-modulating treatment for coccidiosis in broiler chickens. The study aims to confirm the positive effects of Zivo's non-antibiotic alternative, including reduced mortality and improved bird growth rates. The study will also analyze secondary benefits such as protection of intestinal tissue and reduction of pathogenic bacteria.

Zivo Bioscience announces a 1-for-6 reverse stock split to regain compliance with Nasdaq listing requirements.